M. Amoury

发表

Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.

F. Kiessling, R. Fischer, A. Pardo, 2016, Cancer letters.

A novel approach for targeted elimination of CSPG4‐positive triple‐negative breast cancer cells using a MAP tau‐based fusion protein

F. Kiessling, R. Fischer, G. Fey, 2016, International Journal of Cancer.

EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein

R. Fischer, T. Thepen, S. Barth, 2014, Molecular Cancer Therapeutics.

Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand

I. Meinhold-Heerlein, E. Stickeler, R. Fischer, 2016, Oncotarget.

SNAP-tag technology: a powerful tool for site specific conjugation of therapeutic and imaging agents.

S. Barth, A. F. Hussain, M. Amoury, 2013, Current pharmaceutical design.

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo

T. Brümmendorf, R. Fischer, T. Thepen, 2016, Oncotarget.

Leptin Receptor Signaling in T Cells Is Required for Th17 Differentiation

Ana I. Domingos, P. Moraes-Vieira, Aneta Rogoz, 2015, The Journal of Immunology.

CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release

B. Keyt, M. Kotturi, P. Hinton, 2022, Blood.

Differential diagnostic use of interleukin patterns in patients being monitored after transplantation.

P. Fornara, M. Amoury, H. Heynemann, 2001, Clinica chimica acta; international journal of clinical chemistry.

Required for Th17 Differentiation Leptin Receptor Signaling in T Cells Is

P. Moraes-Vieira, Aneta Rogoz, Kihyun Lee, 2015 .

SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.

A. Pardo, S. Barth, W. Helfrich, 2013, Current pharmaceutical design.